个人简介：

王艺瑾，南方科技大学医学院副教授，博士生导师。2012 年和 2016 年分别于荷兰瓦赫宁根大学与研究中心、荷兰伊拉斯姆斯大学医学中心获得硕士和博士学位。美国伊利诺伊大学访问学者。主要研究方向为感染及代谢性肝病免疫调节机制。已发表论文50余篇，其中以第一/通讯作者在 Science Advances, Lancet Respiratory Medicine，Gastroenterology，Journal of Hepatology，Hepatology，EbioMedicine, Metabolism 等知名权威期刊发表论文 30余篇，总影响因子 400 余分，他引1万余次；入选 2022 全球前 2% 科学家榜单；相关成果多次被欧洲、亚太国际肝病年会选为口头报告并获青年科学家奖。以第一发明人申请肝炎、脂肪肝及酒精肝治疗策略相关专利6项。主持国家自然科学基金3项，省部级课题5项。获北京市科技新星、广东省珠江人才、深圳市海外高层次人才。基于本人在戊型肝炎研究领域的突出成绩，牵头成立了中国戊型肝炎研究协作组(CCSHE)，并牵头发布《中国戊型病毒性肝炎院内筛查管理流程专家共识（2023年版）》。

研究方向主要为（1）戊型肝炎转化研究。近十年重点研究病毒-宿主互作、病毒学和免疫学发病机制、免疫应答及炎症发生、组织损伤机制、慢性化机制、重症化机制、临床精准诊断、预后判断及抗病毒治疗策略（2026 Free Radical Bio Med; 2025 Cell Mol Life Sci；2022 Science Advances; 2022 Hepatology; 2018 Gastroenterology; 2014 Gastroenterology; 2018 EBioMedicine; 2019 Liver Int）；（2）其他重大传染病，包括丙型肝炎、乙型肝炎、新冠等疾病发生及损伤机制研究（2020 LRM; 2020 Journal of hepatology; 2023 Metabolism; 2019 EBioMedicine; 2020 JCI Insight;）；（3）非感染性肝病，包括酒精性脂肪肝、代谢性肝病、药物性肝损伤、肝癌等发病机制研究。(2026 JHEP Reports；2025 Clin Transl Med；2023 Metabolism; 2023 Cancer Science; 2022 Alimentary Pharmacology & Therapeutics; 2019 J Gastroenterol)

教育背景：

2012/11–2016/09，荷兰伊拉斯姆斯大学医学中心，肝肠病学，博士

2010/09–2012/08，荷兰瓦赫宁根大学与研究中心，生物技术医学方向，硕士

2006/09–2010/07，南京医科大学，生物技术，学士

工作经历：

2020/11-至今，  南方科技大学医学院，副教授 

2016/09-2020/10， 解放军总医院第五医学中心，病理诊断与研究中心，副研究员

获奖情况及荣誉：

2026，欧洲肝病学会（EASL) Full Bursary Award（课题组）

2026，亚太肝病学会（APASL）Travel Award（课题组）

2025，欧洲肝病学会（EASL) Full Bursary Award（课题组）

2024， 亚太肝病学会（APASL）Travel Award（亚太13人）

2023， 《中国戊型病毒性肝炎院内筛查管理流程专家共识（2023年版）》牵头人

2022， 全球前2%顶尖科学家榜单(World’s Top 2% Scientists 2021)

2022， 华夏医学科技奖 （肝硬化及相关并发症临床诊疗关键机制的研究与应用）

2022， 广东省珠江人才计划青年拔尖人才

2021， 深圳市孔雀人才（B类）

2021,   中华医学科技奖医学科学技术奖 （乙肝肝硬化及相关并发症临床诊疗关键机制的研究与应用）

2020,   亚太肝病学会 （APASL）Travel Award 

2019， 北京市科技新星

2019， 解放军总医院授予的创新人才建设工程新秀人才

2019， 欧洲肝病学会（EASL）授予的Full Bursary Award

2019， 中美肝病学院 优秀报告奖

2019， 北京医学会 北京肝病年会，优秀论文

2018,   欧洲肝病年会（EASL）授予的Full Bursary Award

2018， 亚太肝病年会（APASL）授予的Full Bursary Award

2018， 北京医学会 北京肝病年会，优秀论文

2017， 荷兰肝病学会（NVGE）授予的 Veldhovenbeurs 奖

2017， 中华医学会 脂肪性肝病联合学术会议，优秀论文

2017， 北京医学会 北京肝病学术年会，优秀论文

2014， 欧洲肝病年会（EASL）授予的Full Bursary Award

研究领域：

1、 线粒体稳态在感染及代谢性疾病中的调控机制

2、 肝炎病毒-宿主互作、抗病毒天然免疫机制、抗病毒策略研究

3、 代谢相关脂肪性肝病、酒精性肝病、肝脏肿瘤发病机制

学术任职：

• 中国研究型医院学会肝病专委会青年委员会副主委

• 中国戊型肝炎研究协作组组长

• 中国研究型医院学会分子诊断医学专业委员会临床分子检验学组副组长

• 广东省临床医学学会肝病诊治与临床研究专业委员会常委

• 广东省临床医学学会脂肪肝专业委员会委员

• 科技部青年人才项目会议评审评委

• 科技部重大专项会议评审评委

• 科技部万人领军人才函评评委

• 国家自然科学基金函评评委

主持项目：

1. 国家自然科学基金面上项目，基于HEV介导炎症反应与干扰素通路信号交互机制的抗病毒策略研究，2024年1月 -2027 年12月

2. 广东省国际科技合作项目，戊型肝炎重症化分子机制及干预策略研究，2023年7月-2025年6月

3. 深圳市协同创新科技计划国际科技合作项目，HEV相关肝衰竭早期预警、短期预后标志物开发及抗病毒治疗策略研究，2023年7月-2025年6月

4. 深圳市自然科学基金面上项目，戊型肝炎病毒调控线粒体DNA促进病毒持续复制的机制研究，2021 年4月-2024 年3月

5. 广东省普通高校重点领域专项，戊型肝炎病毒逃逸天然免疫机制及抗病毒策略研究，2021年1月-2024年8月

6. 南方科技大学科研启动基金，2021年1月-2025年12月

7. 北京市科技新星计划，阻断戊型肝炎病毒逃逸天然免疫的抗病毒策略研究，2019年11月-2022年10月

8. 国家自然科学基金青年基金项目，线粒体动态变化在戊型肝炎病毒持续感染过程中的作用及机制研究， 2019 年1月-2021 年12月

9. 国家自然科学基金面上项目，戊型肝炎病毒体外高复制细胞模型优化及病毒三维结构解析和免疫原性研究， 2018 年1月 -2021 年12月

10. 中国人民解放军总医院创新人才建设工程新秀人才

11. 中国人民解放军总医院“优秀青年科学基金”培育计划

第一发明人申请专利情况：

1. 一种靶向治疗肝癌的多肽抑制剂及其应用

2. 一种CD36抑制剂用于改善肝纤维化PSU412023009 2023-08-28

3. 一种CD36抑制剂与PPARy激活剂用于改善肝纤维化PSU412023010 2023-08-2

4. 一种Pgam5突变质粒在治疗酒精性肝病中的应用PSU412023013 2023-09-22

5. Phb2突变体在治疗酒精性肝病中的应用PSU412023014 2023-09-22

6. 一种AMPK激活剂在抗炎抗病毒中的应用PSU412023015 2023-09-22

7. 一种收集细胞中HEV病毒的方法PSU412023002 2023-06-14

发表论文：

[1] X. Liu, Y. Jiang, C. Wang, J. Li, Y. Zhang, et al, Y. Wang*. Mitochondrial fusion orchestrated by hepatitis E virus couples pro-viral autophagy and innate immune evasion for efficient replication.Free Radical Biology and Medicine,2026; 249: 260-272.

[2] Z. Dai, X. Liu, Y. Liang, G. Zhou, J. Chen, et al, Y. Wang*. CD36–PPARγ–SPP1 axis mediates hepatocyte–macrophage coordination to drive MASLD-related liver fibrosis.JHEP Reports,2026; 8: 101745.

[3] C. Wang, X. Liu, Y. Zhao, S. Liao, J. Zhang, et al, Y. Wang*. AMPK activation by hepatitis E virus infection inhibits viral replication through attenuation of autophagosomes and promotion of innate immunity.Cellular and Molecular Life Sciences,2025; 82: 1420-9071.

[4] K. Liu, Y. Wang, J. Li, J. Zhou, C. Suñer, Y. Wang, et al. Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases and enable development of multitarget therapeutics.Nature Biomedical Engineering,2025; 9: 1848-1868.

[5] R. Li, Z. Wang, L. Cheng, Z. Cheng, et al, Y. Wang*. Coordination of SLC39A1 and DRP1 facilitates HCC recurrence by impairing mitochondrial quality control.Clinical and Translational Medicine,2025; 15: e70362.

[6] Y. Liang, J. Zhang, D. Luo, L. Cheng, Y. Wang*. Deregulation of immune response contributing to fulminant hepatitis in HEV infected pregnant women.Journal of Medical Virology,2024; 96: e29639.

[7] A. Huang, C. Zou, Z. Dai, Y. Sun, J. Wang, Y. Wang*, et al. Mild-moderate alcohol consumption and diabetes are associated with liver fibrosis in patients with biopsy-proven MASLD.Frontiers in Pharmacology,2024; 15: 1437479.

[8] P. He, J. Li, C. Wang, J. Zhang, et al, Y. Wang*. Incidence and risk factors of de novo hepatitis E virus infection after receiving liver transplantation.Journal of Medical Virology,2024; 96: e29939.

[9] H. Zhou, Z.Dai, J. Li, J. Wang, et al, Y. Wang*. TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury.Metabolism,2023; 140: 155383.

[10]Z.Wang, R.Li, G.Yang, Y. Wang*. Cancer stem cell biomarkers and related signalling pathways.Journal of Drug Targeting,2023; 32: 33-44.

[11] Y. Wang*, P. Ji, Q. Pan. Mitochondrial quality control: prime targets for antiviral therapy?Trends in Pharmacological Sciences,2023; 44: 647-650.

[12]C.Wang, Y. Wang*. The Role and Mechanism of Action of Mitophagy in Various Liver Diseases.Antioxidants & Redox Signaling,2023; 38: 529-549.

[13] Y. Shen, J.-X. Chen, M. Li, Z. Xiang, J. Wu, Y. Wang*. Role of tumor-associated macrophages in common digestive system malignant tumors.World Journal of Gastrointestinal Oncology,2023; 15: 596-616.

[14] R. Li, J. Wang, X. Li, Y. Liang, et al, Y. Wang*. T‐cell receptor sequencing reveals hepatocellular carcinoma immune characteristics according to Barcelona Clinic liver cancer stages within liver tissue and peripheral blood.Cancer Science,2023; 115: 94-108.

[15] J.B. Wang#, A. Huang#, Y. Wang#, D. Ji#, Q.S. Liang, J. Zhao, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial.Alimentary Pharmacology & Therapeutics,2022; 55: 1297-1310.

[16] P. Li, Y. Li, Y. Wang*, J. Liu, M. Lavrijsen, Y. Li, et al. Recapitulating hepatitis E virus–host interactions and facilitating antiviral drug discovery in human liver–derived organoids.SCIENCE ADVANCES,2022; 8: eabj5908.

[17] Y. Li, P. Yu, A.L. Kessler, J. Shu, X. Liu, Z. Liang, Y. Wang*, et al. Hepatitis E virus infection activates NOD‐like receptor family pyrin domain‐containing 3 inflammasome antagonizing interferon response but therapeutically targetable.Hepatology,2021; 75: 196-212.

[18] J. Zhao, Q. Pan, Y. Jiang, H. Liu, Y. Wang*. Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology.Open Forum Infectious Diseases,2020; 7: ofaa107.

[19] Z. Xu#, L. Shi#, Y. Wang#, J. Zhang, L. Huang, C. Zhang, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome.The Lancet Respiratory Medicine,2020; 8: 420-422.

[20] Y. Wang, S. Liu, Q. Pan, J. Zhao. Chronic hepatitis E in an immunocompetent patient.Clinics and Research in Hepatology and Gastroenterology,2020; 44: e66-e68.

[21] Y. Wang, S. Liu, H. Liu, W. Li, F. Lin, L. Jiang, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.Journal of Hepatology,2020; 73: 807-816.

[22] S. Li#, L. Jiang#, X. Li#, F. Lin#, Y. Wang#, B. Li#, J Jiang#, et al. Clinical and pathological investigation of patients with severe COVID-19.JCI Insight,2020; 5: 2379-3708.

[23] M. Li, L. Wang, Y. Wang, S. Zhang, G. Zhou, R. Lieshout, et al. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth.Cells,2020; 9: 121.

[24] Y. Gao#, Y. Wang#, H. Liu#, Z. Liu, J. Zhao. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis.Digestive and Liver Disease,2020; 52: 637-643.

[25] M. Yang, L. Jiang, Y. Wang, X. Li, G. Zhou, Z. Zou, et al. Step Layered Combination of Noninvasive Fibrosis Models Improves Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.J Gastrointestin Liver Dis,2019; 28: 289-296.

[26] J. Wu, X. Zhang, H. Liu, N. Guo, Q. Pan, Y. Wang*. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection.Clinical Biochemistry,2019; 63: 24-31.

[27] Y. Wang, H. Rao, X. Chi, B. Li, H. Liu, L. Wu, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.eBioMedicine,2019; 46: 227-235.

[28] Y. Wang*, H. Liu, S. Liu, C. Yang, Y. Jiang, S. Wang, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case‐control study.Liver International,2019; 39: 2291-2300.

[29] L. Wang, Y. Wang*, S. Liu, X. Zhai, G. Zhou, F. Lu, J. Zhao. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.Journal of Gastroenterology,2019; 54: 1096-1105.

[30] C. Qu, S. Zhang, Y. Li, Y. Wang, M.P. Peppelenbosch, Q. Pan. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections.Reviews in Medical Virology,2019; 29: e2075.

[31] S. Zhang, C. Qu, Y. Wang, W. Wang, Z. Ma, M.P. Peppelenbosch, Q. Pan. Conservation and variation of the hepatitis E virus ORF2 capsid protein.Gene,2018; 675: 157-164.

[32] H. Zhang, H. Rao, Y. Wang, J. Wang, X. Kong, Y. Ji, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection.Journal of Gastroenterology and Hepatology,2018; 34: 458-465.

[33] Y. Wang*, S. Wang, J. Wu, Y. Jiang, H. Zhang, S. Li, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China.EBioMedicine,2018; 36: 122-130.

[34] Y. Wang, G. Chen, Q. Pan, J. Zhao. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient.Gastroenterology,2018; 154: 1199-1201.

[35] W. Wang, Y. Wang, C. Qu, S. Wang, J. Zhou, W. Cao, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response.Hepatology,2018; 67: 2096-2112.

[36] C. Qu, S. Zhang, W. Wang, M. Li, Y. Wang, M. van der Heijde-Mulder, et al. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target.The FASEB Journal,2018; 33: 1008-1019.

[37] L. Jiang, M. Yang, X. Li, Y. Wang, G. Zhou, J. Zhao. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte–Stellate Cell Crosstalk.The Journal of Clinical Endocrinology & Metabolism,2018; 103: 3974-3985.

[38] X. Zhou, F. Huang, L. Xu, Z. Lin, F.M.S. de Vrij, A.C. Ayo-Martin,Y. Wang, et al. Hepatitis E Virus Infects Neurons and Brains.The Journal of Infectious Diseases,2017; 215: 1197-1206.

[39] L. Xu, W. Wang, Y. Li, X. Zhou, Y. Yin, Y. Wang, et al. RIG‐I is a key antiviral interferon‐stimulated gene against hepatitis E virus regardless of interferon production.Hepatology,2017; 65: 1823-1839.

[40] W. Wang, Y. Yin, L. Xu, J. Su, F. Huang, Y. Wang, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections.Science Signaling,2017; 10: eaah4248.

[41] W. Wang, Y. Wang, Y. Debing, X. Zhou, Y. Yin, L. Xu, et al. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.Antiviral Research,2017; 140: 1-12.

[42] W. Dang, Y. Yin, Y. Wang, W. Wang, J. Su, D. Sprengers, et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication.Antimicrobial Agents and Chemotherapy,2017; 61: e01095-01017.

[43] Y. Yin, Y. Wang, W. Dang, L. Xu, J. Su, X. Zhou, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development.Antiviral Research,2016; 133: 41-49.

[44] L. Xu, X. Zhou, W. Wang, Y. Wang, Y. Yin, L.J.W. van der Laan, et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN‐stimulated genes.The FASEB Journal,2016; 30: 3352-3367.

[45] Y. Wang, W. Wang, L. Xu, X. Zhou, E. Shokrollahi, K. Felczak, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.Antimicrobial Agents and Chemotherapy,2016; 60: 2834-2848.

[46] W. Wang, L. Xu, J.H. Brandsma, Y. Wang, M.S. Hakim, X. Zhou, et al. Convergent Transcription of Interferon-stimulated Genes by TNF-α and IFN-α Augments Antiviral Activity against HCV and HEV.Scientific Reports,2016; 6: 25482.

[47] X. Zhou, L. Xu, Y. Wang, W. Wang, D. Sprengers, H.J. Metselaar, et al. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.Antiviral Research,2015; 124: 11-19.

[48] X. Zhou, L. Xu, W. Wang, K. Watashi, Y. Wang, D. Sprengers, et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.Journal of Viral Hepatitis,2015; 23: 294-304.

[49] Y. Yin, M. Bijvelds, W. Dang, L. Xu, A.A. van der Eijk, K. Knipping, Y. Wang, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids.Antiviral Research,2015; 123: 120-131.

[50] X. Zhou, Y. Wang, H.J. Metselaar, H.L.A. Janssen, M.P. Peppelenbosch, Q. Pan. Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathway.Journal of Hepatology,2014; 61: 746-754.

[51] Y. Wang, X. Zhou, Y. Debing, K. Chen, L.J.W. Van Der Laan, J. Neyts, et al. Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus.Gastroenterology,2014; 146: 1775-1783.

[52] Y. Wang, H.J. Metselaar, M.P. Peppelenbosch, Q. Pan. Chronic hepatitis E in solid-organ transplantation.Current Opinion in Infectious Diseases,2014; 27: 303-308.

[53] L.P.M.P. Hemachandra, H. Patel, R.E.P. Chandrasena, J. Choi, S.C. Piyankarage, S. Wang, Y. Wang, et al. SERMs Attenuate Estrogen-Induced Malignant Transformation of Human Mammary Epithelial Cells by Upregulating Detoxification of Oxidative Metabolites.Cancer Prevention Research,2014; 7: 505-515.

[54] Y. Debing, S.U. Emerson, Y. Wang, Q. Pan, J. Balzarini, K. Dallmeier, J. Neyts. Ribavirin Inhibits In Vitro Hepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon.Antimicrobial Agents and Chemotherapy,2014; 58: 267-273.

[55] 李兰娟,吴健,王艺瑾,祁小龙,曹红翠.中国戊型病毒性肝炎院内筛查管理流程专家共识（2023年版）.临床肝胆病杂志,2023; 39: 785-794.

[56] 陈俞心,王艺瑾.戊型肝炎病毒感染重症化和慢性化的机制.临床肝胆病杂志,2023; 39: 2530-2537.